Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21184185 | 1.00 | EPHX1 (0.58) | EPHX1NAAAFAAHACHETSHR | |
| SCHEMBL15796558 | 1.00 | EPHX1 (0.58) | EPHX1NAAAFAAHACHETSHR | |
| Hydrochloric Acid SCHEMBL15569656 | 0.98 | EPHX1 (0.56) | EPHX1NAAAFAAHACHETSHR | |
| SCHEMBL2846894 | 0.98 | EPHX1 (0.55) | EPHX1NAAAFAAHACHETSHR | |
| SCHEMBL2034542 | 0.98 | EPHX1 (0.55) | EPHX1NAAAFAAHACHETSHR | |
| SCHEMBL807264 | 0.92 | ALDH1A1 (0.50) | EPHX1NAAAACHETSHRZDHHC7 | |
| SCHEMBL14304682 | 0.92 | ALDH1A1 (0.50) | EPHX1NAAAACHETSHRZDHHC7 | |
| SCHEMBL116383 | 0.86 | EPHX1 (0.55) | EPHX1NAAAFAAHACHETSHR | |
| SCHEMBL1744362 | 0.86 | EPHX1 (0.55) | EPHX1NAAAFAAHACHETSHR | |
| SCHEMBL19190109 | 0.84 | HCAR2 (0.38) | EPHX1ACHETSHRZDHHC7HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | EPHX1 2615/4885NAAA 1543/4885FAAH 2352/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | EPHX1 2615/4885NAAA 1543/4885FAAH 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.